ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate (IM), a targeted competitive inhibitor of the BCR-ABL tyrosine kinase, has revolutionized the clinical treatment of chronic myeloid leukemia (CML).